Sep 2026 (Q2 FY27) — Oct 15, 2026
Wise Group plc Q2 FY27 — Strong Volume and Customer Growth Amidst Strategic Investments
Read the full callWise Group earnings: last reported Thu, 15 Oct 2026, for the quarter ended Sep 2026.
Price
YTD: $14.4 on 5 May 2026 → $12.1. High $15.4 (11 May 2026), low $10.4 (11 Jun 2026).
Overview
Call summaries
Wise Group plc Q2 FY27 — Strong Volume and Customer Growth Amidst Strategic Investments
Read the full callEvery analysed call
Financials
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Reserves | — | 1,656 | 2,111 |
| Total liabilities | — | 23,044 | 31,335 |
| Fixed assets | — | 151 | 190 |
| Total assets | — | 24,781 | 33,260 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from operations | 4,075 | 5,720 | 7,554 |
| Cash from investing | -181 | -758 | 1,739 |
| Cash from financing | -148 | -230 | -275 |
| Net cash flow | 3,771 | 4,821 | 9,736 |
| Capital expenditure | -13 | -44 | -20 |
| Free cash flow | 4,062 | 5,675 | 7,534 |
4 filings between Jul 15, 2026 and Jul 16, 2026.
Purchases
None
No insider bought shares.
Sales
$1.29M
2 sales by 2 insiders
| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Peiris Nilan | — | $749.2K | Jul 16, 2026 |
| Sinha Harsh | — | $541.4K | Jul 16, 2026 |
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jul 16, 2026 | Peiris Nilan Chief Product Officer | Sale | 58,262 | $749.2K |
| Jul 16, 2026 | Sinha Harsh Chief Technology Officer | Sale | 42,101 | $541.4K |
| Jul 15, 2026 | Peiris Nilan Chief Product Officer | Option exercise | 105,240 | — |
| Jul 15, 2026 | Sinha Harsh Chief Technology Officer | Option exercise | 105,240 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow Wise Group plc and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading